We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
DENTSPLY (XRAY) Renews Partnership with Pacific Dental
Read MoreHide Full Article
York, PA-based DENTSPLY SIRONA Inc. (XRAY - Free Report) , a dental solutions company, recently announced that it has renewed its strategic partnership with Pacific Dental Services, LLC.
Stock Performance
The price performance of the stock has been unfavorable in the last three months. DENTSPLY SIRONA rose only 1.50%, underperforming the Zacks classified Medical/Dental-Supplies sub-industry’s gain of almost 7.54%. The current level compares unfavorably with the S&P 500’s return of 3.90% over the same time frame.
The estimate revision trend for the stock has been dismal, with 10 estimates moving south in the last two months and no estimate moving north. Notably, the current year estimate for the stock fell 2 cents to $2.83 per share over the same time frame.
Coming back to the news, the duo’s new agreement is for a period of five years. Per the agreement, DENTSPLY SIRONA will provide Pacific Dental Services and its network comprising more than 1,600 dentists with access to its range of consumables offering, marketing, sponsorship, and training opportunities. The agreement originally was signed between the two parties in 2012.
We feel the renewal of the agreement is a smart move on the part of DENTSPLY SIRONA as Pacific Dental network consists of over 580 centres in 17 states. Pacific Dental-supported offices have implemented the company’s CEREC technology system and are the world’s largest network of CEREC users. Management estimates that during the tenure of the present agreement, the number of such offices utilizing DENTSPLY SIRONA technologies could exceed 800.
Headquartered in York, PA, DENTSPLY SIRONA is a global leader in the design, development, manufacture and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products.
Zacks Rank & Key Picks
Currently, DENTSPLY SIRONA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Inogen and Luminex Laboratories sport a Zacks Rank #1 (Strong Buy), while IDEXX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 90.2%.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock posted a positive earnings surprise of 237.5% in the last reported quarter.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.37%. Additionally, the stock represents an impressive one-year return of 80.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
DENTSPLY (XRAY) Renews Partnership with Pacific Dental
York, PA-based DENTSPLY SIRONA Inc. (XRAY - Free Report) , a dental solutions company, recently announced that it has renewed its strategic partnership with Pacific Dental Services, LLC.
Stock Performance
The price performance of the stock has been unfavorable in the last three months. DENTSPLY SIRONA rose only 1.50%, underperforming the Zacks classified Medical/Dental-Supplies sub-industry’s gain of almost 7.54%. The current level compares unfavorably with the S&P 500’s return of 3.90% over the same time frame.
The estimate revision trend for the stock has been dismal, with 10 estimates moving south in the last two months and no estimate moving north. Notably, the current year estimate for the stock fell 2 cents to $2.83 per share over the same time frame.
Coming back to the news, the duo’s new agreement is for a period of five years. Per the agreement, DENTSPLY SIRONA will provide Pacific Dental Services and its network comprising more than 1,600 dentists with access to its range of consumables offering, marketing, sponsorship, and training opportunities. The agreement originally was signed between the two parties in 2012.
We feel the renewal of the agreement is a smart move on the part of DENTSPLY SIRONA as Pacific Dental network consists of over 580 centres in 17 states. Pacific Dental-supported offices have implemented the company’s CEREC technology system and are the world’s largest network of CEREC users. Management estimates that during the tenure of the present agreement, the number of such offices utilizing DENTSPLY SIRONA technologies could exceed 800.
Headquartered in York, PA, DENTSPLY SIRONA is a global leader in the design, development, manufacture and marketing of dental consumables, dental laboratory products, dental specialty products and consumable medical device products.
Zacks Rank & Key Picks
Currently, DENTSPLY SIRONA carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the broader medical sector include Inogen Inc. (INGN - Free Report) , Luminex Corporation and IDEXX Laboratories, Inc. (IDXX - Free Report) . Inogen and Luminex Laboratories sport a Zacks Rank #1 (Strong Buy), while IDEXX carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks Rank #1 stocks here.
Inogen has a long-term expected earnings growth rate of 17.50%. Notably, the stock represents an impressive one-year return of 90.2%.
Luminex has a long-term expected earnings growth rate of 16.3%. The stock posted a positive earnings surprise of 237.5% in the last reported quarter.
IDEXX Laboratories has a long-term expected earnings growth rate of 19.37%. Additionally, the stock represents an impressive one-year return of 80.5%.
Looking for Stocks with Skyrocketing Upside?
Zacks has just released a Special Report on the booming investment opportunities of legal marijuana.
Ignited by new referendums and legislation, this industry is expected to blast from an already robust $6.7 billion to $20.2 billion in 2021. Early investors stand to make a killing, but you have to be ready to act and know just where to look. See the pot trades we're targeting>>